{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TBL+12&page=41", "query": { "intervention": "TBL 12", "page": 41 }, "page_size": 10 }, "pagination": { "page": 41, "page_size": 10, "total_count": 1229, "total_pages": 123, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TBL+12&page=42&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TBL+12&page=40&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-08T22:26:52.607Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02932150", "title": "Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "TAF", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 150, "start_date": "2016-11", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-11-08T22:26:52.607Z", "location_count": 15, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02932150" }, { "nct_id": "NCT04388254", "title": "Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Simufilam 100 mg oral tablet", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cassava Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 220, "start_date": "2020-03-24", "completion_date": "2023-11-09", "has_results": true, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-11-08T22:26:52.607Z", "location_count": 15, "location_summary": "Gilbert, Arizona • Surprise, Arizona • Imperial, California + 12 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" }, { "city": "Imperial", "state": "California" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04388254" }, { "nct_id": "NCT03655431", "title": "Home Exercise Telerehabiliation for MS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Telerehabilitation", "type": "OTHER" }, { "name": "Standard treatment", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Shane.Chanpimol", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2016-10-01", "completion_date": "2021-01-01", "has_results": false, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-11-08T22:26:52.607Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03655431" }, { "nct_id": "NCT00066469", "title": "Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorder" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 55, "start_date": "2004-04", "completion_date": "2013-12-31", "has_results": true, "last_update_posted_date": "2019-08-06", "last_synced_at": "2026-11-08T22:26:52.607Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066469" }, { "nct_id": "NCT03016819", "title": "Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alveolar Soft Part Sarcoma", "Leiomyosarcoma", "Synovial Sarcoma", "Soft-Tissue Sarcoma" ], "interventions": [ { "name": "AL3818", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "AL3818 or placebo", "type": "DRUG" }, { "name": "Midazolam 2 mg for CYP3A4 phenotyping", "type": "DRUG" }, { "name": "Digoxin (0.25mg)", "type": "DRUG" }, { "name": "Rosuvastatin 10 mg tablet.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advenchen Laboratories, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2017-08-15", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-11-08T22:26:52.607Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03016819" }, { "nct_id": "NCT04629300", "title": "Supportive Care Mobile Application for Patients With NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non Small Cell Lung Cancer", "Quality of Life", "Coping Skills" ], "interventions": [ { "name": "Supportive Care Mobile Application", "type": "BEHAVIORAL" }, { "name": "Usual Care", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2021-10-15", "completion_date": "2024-07-31", "has_results": false, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-11-08T22:26:52.607Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Danvers, Massachusetts • Milford, Massachusetts + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Danvers", "state": "Massachusetts" }, { "city": "Milford", "state": "Massachusetts" }, { "city": "Newton", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629300" }, { "nct_id": "NCT02994056", "title": "Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "SOF/VEL", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-01-23", "completion_date": "2018-12-12", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-11-08T22:26:52.607Z", "location_count": 10, "location_summary": "Tampa, Florida • Chicago, Illinois • Catonsville, Maryland + 7 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Catonsville", "state": "Maryland" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02994056" }, { "nct_id": "NCT00302952", "title": "Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Lovastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 64, "start_date": "2007-11-06", "completion_date": "2012-04-30", "has_results": true, "last_update_posted_date": "2022-09-07", "last_synced_at": "2026-11-08T22:26:52.607Z", "location_count": 15, "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00302952" }, { "nct_id": "NCT06146504", "title": "Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Candida Systemic", "Candida Albicans Infection", "Candida Infection" ], "interventions": [ { "name": "CanXida Remove (Formula RMV)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "CanXida", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 60, "start_date": "2023-11-30", "completion_date": "2024-06-28", "has_results": false, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-11-08T22:26:52.607Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06146504" }, { "nct_id": "NCT05841238", "title": "A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Obese" ], "interventions": [ { "name": "LY3502970", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 52, "start_date": "2023-04-26", "completion_date": "2023-11-13", "has_results": true, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-11-08T22:26:52.607Z", "location_count": 3, "location_summary": "Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05841238" } ] }